Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies

Cancer Treatment Reviews

Volumn 38, Issue 2, 2012, Pages 127-132

  Escudier, Bernard ^a   Osanto, Susanne ^b   Ljungberg, Börje ^c   Porta, Camillo ^d   Wagstaff, John ^e   Mulders, Peter ^f   Gore, Martin ^g   Bex, Axel ^h   Bellmunt, Joaquim ⁱ   Bracarda, Sergio ^j   Franklin, Alex ^e   Honoré, Per Hartvig ^k   Ravaud, Alain ^l   Steijn, Jeanne van ^b   Aziz, Zeba ^m   Akaza, Hideyuki ⁿ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UMEÅ UNIVERSITY   (Sweden)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e SINGLETON HOSPITAL   (United Kingdom)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ HOSPITAL DEL MAR   (Spain)

^j IRCCS POLICLINICO SAN DONATO   (Italy)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l HÔPITAL SAINT ANDRÉ   (France)

^m ALLAMA IQBAL MEDICAL COLLEGE   (Pakistan)

ⁿ UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

Multidisciplinary management; Renal cell carcinoma; Targeted agents

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER DIAGNOSIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLEAR CELL CARCINOMA; COMMUNITY CARE; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GENERAL PRACTITIONER; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MEDICAL STAFF; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIDISCIPLINARY MANAGEMENT; NAUSEA; NEPHRECTOMY; ONCOLOGIST; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TOXICITY; UROLOGIST; VOMITING;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 84856322838     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.006     Document Type: Review

References (41)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. de Reijke T.M., Bellmunt J., van Poppel H., et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Kidney Cancer version 1, 2011. Accessed 28.1.2011.
4. Vogelzang N.J. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol 2006, 24:1-2.
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
7. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
8. Bellmunt J., Negrier S., Escudier B., et al. The medical treatment of metastatic renal cell carcinoma: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009, 69:64-72.
9. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously-treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
10. Escudier B., Bellmunt J., Negrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
11. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
12. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
13. Gruenwald V., Kalanovic D., Merseburger A.S. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J Urol 2010, 28:343-351.
14. Edmonds K., Spencer-Shaw A. Managing adverse events associated with sorafenib in renal cell carcinoma. Br J Nurs 2010, 19:58-60.
15. Creel P.A. Management of mTOR inhibitor side effects. Clin J Oncol Nurs 2009, 13(Supp):19-23.
16. Flanigan R.C., Mickisch C., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cell cancer: a combined analysis. J Urol 2004, 171:1071-1076.
17. Choueiri TK, Xie W, Kollmansberger CK et al. The impact of cytoreductive nephrectomy in patients with metastatic renal carcinoma treated with VEGF-targeted therapy. Proc ASCO Genitourinary Cancers Symposium 2010, Abs 311.
18. Belldegrun A.S., Klatte T., Shuch B., et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008, 113:2457-2463.
19. Zisman A., Wieder J.A., Pantuck A.J., et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003, 169:909-916.
20. Ljungberg B., Stenling R., Osterdahl B., et al. Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol 1995, 154:1681-1684.
21. Wood L.S. New therapeutic strategies for renal cell carcinoma. Urologic Nursing 2010, 30:40-54.
22. Maier K. Our capability needs a goal-patients need our competence. Eur J Oncology Pharmacy 2009, 3:3.
23. Negrier S. Best use of targeted agents for the treatment of advanced renal cell carcinoma. Eur J Oncology Pharmacy 2009, 3:8-12.
24. Lenihan D.J. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?. J Clin Oncol 2008, 32:5154-5155.
25. Ewer M.S., Lenihan D.J., Khakoo A.Y. Sunitinib-related cardiotoxicity: an interdisciplinary issue. Nature Reviews Cardiology 2008, 5:364-365.
26. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
27. Taylor C., Munro A.J., Glynne-Jones R., et al. Multidisciplinary team working in cancer: what is the evidence?. Br Med J 2010, 340:c951.
28. Fleissig A., Jenkins V., Catt S., Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK?. Lancet Oncol 2006, 7:886-888.
29. Samuel DG. MDT=Multidisciplinary teaching. Br Med J 2010; Rapid response 7 April.
30. Blennerhassett M. Patient narratives hold the evidence for MDTs. Br Med J 2010; rapid response 25 March.
31. Blobel B., Pharow P. Results of European projects improving security of distributed health information systems. Stud Health Technol Inform 1998, 52:1119-1123.
32. Prince-Paul M., Burant C.J., Saltzman J.N., et al. The effects of integrating an advanced practice palliative care nurse in a community oncology center: a pilot study. J Support Oncol 2010, 8:21-27.
33. Hussainy S.Y., Marriott J.L., Beattie J., et al. A palliative care flexible education program of Australian community pharmacists. Am J Pharm Educ 2010, 74:24.
34. Ljungberg B, Cowan N, Hanbury DC et al. Guidelines on renal cell carcinoma 2010. European Association of Urology. accessed 4.5.2010. http://www.uroweb.org.
35. Escudier B., Kataja V. On behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v137-v139.
36. Ljungberg B., Cowan N.C., Hanbury D.C., et al. For the European Association of Urology Guidelines Group. EAU Guidelines in renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
37. Uemura H., Shinohara N., Yuasa T., et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Japanese J Clin Oncol 2009, 40:194-202.
38. Fujioka T., Obara W. Int J Urol 2009, 16:339. The Committee for Establishment of Guidelines of the Japanese Urological Association. Evidence based clinical practice guidelines for renal cell carcinoma (JUA 2007 edition).
39. National Comprehensive Cancer Network Asian Consensus Statement on kidney cancer, 2009 accessed 27.9.10. http://www.nccn-asia.org.
40. Gore M., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded access trial. Lancet Oncol 2009, 10:757-763.
41. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.